期刊
JOURNAL OF NEUROSCIENCE
卷 28, 期 42, 页码 10451-10459出版社
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.1092-08.2008
关键词
ALS; VEGF-B; Flt1; motor neuron degeneration; intracerebroventricular delivery; therapy
资金
- Research Foundation Flanders (FWO), Belgium [G 0210.07]
- Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)
- Schenking Rimaux-Bartier
- Geneeskundige stichting Koningin Elisabeth
- Geconcerteerde Onderzoeksacties-Katholieke Universiteit Leuven
- Methusalem
- Muscular Dystrophy Association
- ALS Association
- Belgian Federal Science Policy Office [P5/19, P6/43]
Although vascular endothelial growth factor-B (VEGF-B) is a homolog of the angiogenic factor VEGF, it has only minimal angiogenic activity, raising the question of whether this factor has other (more relevant) biological properties. Intrigued by the possibility that VEGF family members affect neuronal cells, we explored whether VEGF-B might have a role in the nervous system. Here, we document that the 60 kDa VEGF-B isoform, VEGF-B-186, is a neuroprotective factor. VEGF-B-186 protected cultured primary motor neurons against degeneration. Mice lacking VEGF-B also developed a more severe form of motor neuron degeneration when intercrossed with mutant SOD1 mice. The in vitro and in vivo effects of VEGF-B-186 were dependent on the tyrosine kinase activities of its receptor, Flt1, in motor neurons. When delivered intracerebroventricularly, VEGF-B-186 prolonged the survival of mutant SOD1 rats. Compared with a similar dose of VEGF, VEGF-B-186 was safer and did not cause vessel growth or blood-brain barrier leakiness. The neuroprotective activity of VEGF-B, in combination with its negligible angiogenic/permeability activity, offers attractive opportunities for the treatment of neurodegenerative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据